Old Web
English
Sign In
Acemap
>
authorDetail
>
Jeffrey P. Hodge
Jeffrey P. Hodge
Duke University
Medicine
Pharmacokinetics
Pathology
Cancer research
Pazopanib
4
Papers
336
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Phase I Dose-Finding Study of Pazopanib in Hepatocellular Carcinoma: Evaluation of Early Efficacy, Pharmacokinetics, and Pharmacodynamics
2011
Clinical Cancer Research
Thomas Yau
Pei-Jer Chen
Pierre Chan
Corinne M Curtis
Philip S. Murphy
Albert Benjamin Suttle
Jennifer L. Gauvin
Jeffrey P. Hodge
Mohammed M. Dar
Ronnie Tung-Ping Poon
Show All
Source
Cite
Save
Citations (71)
Response to a Novel Multitargeted Tyrosine Kinase Inhibitor Pazopanib in Metastatic Merkel Cell Carcinoma
2009
Journal of Clinical Oncology
Matthew S. Davids
Amanda Charlton
Swee Siang Ng
Mei Ling Chong
Kevin Laubscher
Mohammed M. Dar
Jeffrey P. Hodge
Richie Soong
Boon Cher Goh
Show All
Source
Cite
Save
Citations (74)
Phase I Study of 506U78 Administered on a Consecutive 5-Day Schedule in Children and Adults With Refractory Hematologic Malignancies
2005
Journal of Clinical Oncology
Joanne Kurtzberg
T. J. Ernst
M. J. Keating
Varsha V Gandhi
Jeffrey P. Hodge
David F. Kisor
Joanne J. Lager
C. Stephens
J. Levin
T. Krenitsky
Gertrude B. Elion
Beverly S. Mitchell
Show All
Source
Cite
Save
Citations (131)
Pharmacokinetics of Nelarabine and 9-Beta-d-Arabinofuranosyl Guanine in Pediatric and Adult Patients During a Phase I Study of Nelarabine for the Treatment of Refractory Hematologic Malignancies
2000
Journal of Clinical Oncology
David F. Kisor
William K Plunkett
Joanne Kurtzberg
Beverly S. Mitchell
Jeffrey P. Hodge
Timothy Ernst
M. J. Keating
Varsha V Gandhi
Show All
Source
Cite
Save
Citations (60)
1